It is with passion, enthusiasm, and the desire
  to preserve Tim's name and spirit that we created the
    Timothy Aycock Melanoma Research Foundation
Timothy and family
Our mission is to continue his heroic battle against melanoma by increasing awareness about this lethal disease, contributing to cutting-edge medical research, and providing information to those who struggle with melanoma's devastating effects.

Your Donations at Work

The Timothy Aycock Melanoma Research Foundation has been able to continue Timís heroic battle against melanoma due to your generosity and commitment in helping to find a cure for this terrible disease. During his eight year battle with melanoma, Tim continued to seek out new and innovative treatments to combat this disease. One way we are keeping Tim's spirit alive is by making investments in cutting edge and innovative melanoma research. It was these types of research programs which generated new alternatives and choices of treatments which helped to increase Timís lifespan.

Your donations have supported nine trials conducted by the John Wayne Cancer Institute (JWCI) related to the Canvaxin polyvalent cancer vaccine. Canvaxin has been proven to prolong survival in patients who receive this vaccine after surgery for melanoma. In fact, the survival rate for patients with Stage IV melanoma who received the Canvaxin polyvalent cancer vaccine had a survival rate which was nearly double that of the non-vaccine group at five years (39% vs. 20%).

We have also been able to support the sentinel node trial (MSLT-1) which involved 2000 patients and produced very positive results. The trial confirmed that the "Blue Node" procedure developed by Dr. Donald Morton, who is the Chief of the Melanoma Program at the John Wayne Cancer Institute, improved the survival of melanoma patients with tumor involved nodes. These results were published in the prestigious New England Journal of Medicine and were featured in the Wall Street Journal on September 28, 2006.

We look forward to our continued investments to the melanoma research community in the years ahead. We are off to a phenomenal start but our finest hours are yet to come as we all anticipate the day when a cure is developed for advanced stages of melanoma.